Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Anthem Blue Cross hosts Hmong Health Awareness Fair with local health and community agencies

Tomorrow, Anthem Blue Cross State Sponsored Business will team with local health and community agencies to host the Hmong Health Awareness Fair. Local health and community organizations will be on hand to provide local families free health screenings, vaccines and health information. The health fair will take place from 9:00 a.m. to 3: p.m. at the Asian Village Shopping Center located at 4903 E. Kings Canyon Road.

18 Sep 2010

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

CytoGenix, Inc. today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.

18 Sep 2010

Walgreens pharmacists in California offer immunizations that protect against pertussis

With the state of California on pace for the worst epidemic of pertussis, or whooping cough, in nearly five decades, officials from the Centers for Disease Control and Prevention as well as the California Department of Public Health continue to strongly encourage vaccination to help increase immunity and stop the spread of the disease for all Californians.

18 Sep 2010

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today it has initiated the first human trial of plant-produced H1N1 influenza vaccine at the Walter Reed Army Institute of Research Clinical Trials Center (WRAIR-CTC).

18 Sep 2010

Health premiums rise as states consider how they'll implement reforms

Overall health insurance premiums rose 7 percent in 2009, even as the number of people with health coverage fell. "Individual premium revenues rose 15 percent while group premiums, which involve mostly employers, rose nearly 3 percent, according to the report from the National Association of Insurance Commissioners, an organization whose prominence has grown following passage of the new U.S. health reform law."

18 Sep 2010

Research Roundup: Assessing physician quality; Community health centers' future; Why doctors take gifts; Access to HIV treatment

Archives of Internal Medicine: Associations Between Physician Characteristics And Quality Of Care - Since "most patients do not have access to physician quality measures," they are often encouraged to use public information such as malpractice claims and board certification status to chose a doctor, according to this report that used 2004-2005 insurance claims from about 10,000 Massachusetts physicians for more than 1.13 million adults.

18 Sep 2010

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.

18 Sep 2010

Simian immunodeficiency virus is at least 32,000 to 75,000 years old

An ancestor of HIV that infects monkeys is thousands of years older than previously thought, suggesting that HIV, which causes AIDS, is not likely to stop killing humans anytime soon, finds a study by University of Arizona and Tulane University researchers.

17 Sep 2010

Johnson & Johnson, Crucell announce advanced negotiations for potential public offer

Johnson & Johnson and Crucell N.V. today announced that they are in advanced negotiations for a potential public offer by Johnson & Johnson or an affiliate for all outstanding ordinary shares of Crucell not already held by Johnson & Johnson and its affiliates.

17 Sep 2010

Study identifies venous thromboembolism risk factors after THR surgery

Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.

17 Sep 2010

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

Rural hospitals in Minnesota contribute to insurance premiums for poor patients

News outlets report on rural hospitals in Minnesota, a new insurer contract for a Florida hospital and possible restrictions on a pending for-profit hospital system in Massachusetts.

17 Sep 2010

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.

17 Sep 2010

FDA Advisory Committee recommends approval of Alkermes' VIVITROL for opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL® (naltrexone for extended-release injectable suspension) should be approved for the treatment of opioid dependence.

17 Sep 2010

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

16 Sep 2010

Friendship paradox helps analyze social network, monitor member health to predict flu outbreak

Nicholas Christakis, professor of medicine, medical sociology and sociology at Harvard University, and James Fowler, professor of medical genetics and political science at the University of California, San Diego, used the paradox to study the 2009 flu epidemic among 744 students. The findings, the researchers say, point to a novel method for early detection of contagious outbreaks.

16 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT and the weight loss medication sibutramine (sold as Meridia® in the United States).

16 Sep 2010

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today participated in the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

16 Sep 2010

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens.

16 Sep 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Anthem Blue Cross hosts Hmong Health Awareness Fair with local health and community agencies

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

Walgreens pharmacists in California offer immunizations that protect against pertussis

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

Health premiums rise as states consider how they'll implement reforms

Research Roundup: Assessing physician quality; Community health centers' future; Why doctors take gifts; Access to HIV treatment

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

Simian immunodeficiency virus is at least 32,000 to 75,000 years old

Johnson & Johnson, Crucell announce advanced negotiations for potential public offer

Study identifies venous thromboembolism risk factors after THR surgery

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Rural hospitals in Minnesota contribute to insurance premiums for poor patients

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

FDA Advisory Committee recommends approval of Alkermes' VIVITROL for opioid dependence

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

Friendship paradox helps analyze social network, monitor member health to predict flu outbreak

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in